ATE309200T1 - Antikonvulsive und zns-aktive bis-fluoralkylamide - Google Patents

Antikonvulsive und zns-aktive bis-fluoralkylamide

Info

Publication number
ATE309200T1
ATE309200T1 AT98963065T AT98963065T ATE309200T1 AT E309200 T1 ATE309200 T1 AT E309200T1 AT 98963065 T AT98963065 T AT 98963065T AT 98963065 T AT98963065 T AT 98963065T AT E309200 T1 ATE309200 T1 AT E309200T1
Authority
AT
Austria
Prior art keywords
disorders
diseases
compounds
epilepsy
treatment
Prior art date
Application number
AT98963065T
Other languages
English (en)
Inventor
Manuel F Balandrin
Bradford C Vanwagenen
Linda D Artman
Alan L Mueller
Daryl Smith
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE309200T1 publication Critical patent/ATE309200T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98963065T 1997-12-10 1998-12-09 Antikonvulsive und zns-aktive bis-fluoralkylamide ATE309200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6900597P 1997-12-10 1997-12-10
PCT/US1998/026315 WO1999029657A1 (en) 1997-12-10 1998-12-09 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides

Publications (1)

Publication Number Publication Date
ATE309200T1 true ATE309200T1 (de) 2005-11-15

Family

ID=22086084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963065T ATE309200T1 (de) 1997-12-10 1998-12-09 Antikonvulsive und zns-aktive bis-fluoralkylamide

Country Status (11)

Country Link
US (2) US6617358B1 (de)
EP (1) EP1042275B1 (de)
JP (1) JP2001525390A (de)
CN (1) CN1159287C (de)
AT (1) ATE309200T1 (de)
AU (1) AU763245B2 (de)
CA (1) CA2313236A1 (de)
DE (1) DE69832302D1 (de)
IL (1) IL136306A (de)
NZ (2) NZ536524A (de)
WO (1) WO1999029657A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026251A2 (en) 1998-10-30 2000-05-11 Holtzman Jordan L A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
IL153058A0 (en) * 2000-05-24 2003-06-24 Jordan Loyal Holtzman Agents and methods for increasing brain chaperonin levels
US6399641B1 (en) * 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
US7560862B2 (en) * 2004-10-22 2009-07-14 Eastman Kodak Company White OLEDs with a color-compensated electroluminescent unit
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US9212155B2 (en) * 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
JP5746612B2 (ja) * 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
US20110224304A1 (en) * 2008-11-14 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. Biphenylacetamide derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269079A (de) * 1960-09-09 1964-06-25
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
US4603145A (en) * 1983-05-06 1986-07-29 American Cyanamid Company Antiatherosclerotic diphenyl alkanamides
EP0450689A1 (de) * 1990-04-02 1991-10-09 Akzo Nobel N.V. Isochromanderivate
FR2664594B1 (fr) * 1990-07-11 1992-09-18 Adir Polymethylene-imines disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5506268A (en) 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
AU710575B2 (en) * 1994-02-08 1999-09-23 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU3414295A (en) * 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
JP2002511835A (ja) * 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物

Also Published As

Publication number Publication date
NZ536524A (en) 2006-04-28
US20030199589A1 (en) 2003-10-23
NZ524395A (en) 2004-10-29
US6617358B1 (en) 2003-09-09
AU763245B2 (en) 2003-07-17
EP1042275A1 (de) 2000-10-11
DE69832302D1 (de) 2005-12-15
IL136306A (en) 2005-09-25
JP2001525390A (ja) 2001-12-11
EP1042275B1 (de) 2005-11-09
WO1999029657A1 (en) 1999-06-17
IL136306A0 (en) 2001-05-20
AU1817099A (en) 1999-06-28
CA2313236A1 (en) 1999-06-17
CN1284056A (zh) 2001-02-14
CN1159287C (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
WO2004041258A3 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
HUP0401567A2 (hu) CB1 receptor antagonista aktivitással rendelkező új 4,5-dihidro-1H-pirazol-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR0315113A (pt) Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
EA200101134A1 (ru) Одно- и двузамещенные 3-пропил-гамма-аминомасляные кислоты
DE69832302D1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
NZ338016A (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
DE69930662D1 (de) Humane rezeptortyrosinkinase
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
EP1640359A3 (de) Antikonvulsive und zns-aktive bis-fluoroalkylamide
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
BR9807262A (pt) Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila
DE602004019129D1 (de) Verwendung von 1-oxadibenzo äe,hü azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств